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Abstract
Introduction A broad range of stakeholders have
called for randomised evidence on the potential
clinical benefits and harms of proton therapy, a type
of radiation therapy, for patients with breast cancer.
Radiation therapy is an important component of
curative treatment, reducing cancer recurrence and
extending survival. Compared with photon therapy, the
international treatment standard, proton therapy reduces
incidental radiation to the heart. Our overall objective
is to evaluate whether the differences between proton
and photon therapy cardiac radiation dose distributions
lead to meaningful reductions in cardiac morbidity and
mortality after treatment for breast cancer.
Methods We are conducting a large scale, multicentre
pragmatic randomised clinical trial for patients with
breast cancer who will be followed longitudinally for
cardiovascular morbidity and mortality, health-related
quality of life and cancer control outcomes. A total of
1278 patients with non-metastatic breast cancer will be
randomly allocated to receive either photon or proton
therapy. The primary outcomes are major cardiovascular
events, defined as myocardial infarction, coronary
revascularisation, cardiovascular death or hospitalisation
for unstable angina, heart failure, valvular disease,
arrhythmia or pericardial disease. Secondary endpoints
are urgent or unanticipated outpatient or emergency
room visits for heart failure, arrhythmia, valvular disease
or pericardial disease. The Radiotherapy Comparative
Effectiveness (RadComp) Clinical Events Centre will
conduct centralised, blinded adjudication of primary
outcome events.

Strengths and limitations of this study
►► The pragmatic and holistic approach reflects ‘re-

al-world’ clinical practice, identifies subgroups of
patients who might benefit more from proton therapy and helps patients and physicians understand
and apply findings to their own lived experience.
►► Engagement of patients and other essential stakeholders in the design and conduct of large scale
pragmatic randomised control trials of a promising,
but expensive, medical technology will inform future
efforts to conduct holistic, patient-centric and pragmatic comparative effectiveness research as part of
a learning healthcare system.
►► Blinded, centralised adjudication of primary outcomes applies consistent, relevant definitions of
fatal and non-fatal events comprising the major
cardiovascular endpoint to detect possible events
and avoids the influence of investigator or patient
ascertainment bias.
►► The Radiotherapy Comparative Effectiveness
Consortium may have the appearance of conflict of
interest (COI) as it involves centres with proton therapy capabilities. COI concerns are addressed by randomised study design, blinded adjudication of primary
outcome, accountability by the data safety monitoring
board, and declaration, disclosure and management of
COI.
Ethics and dissemination The RadComp trial has
been approved by the institutional review boards of
all participating sites. Recruitment began in February
2016. Current version of the protocol is A3, dated 08
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November 2018. Dissemination plans include presentations at scientific
conferences, scientific publications, stakeholder engagement efforts
and presentation to the public via lay media outlets.
Trial registration number NCT02603341

Introduction
The Pragmatic Randomised Trial of Proton versus Photon
Therapy for Patients with Non-Metastatic Breast Cancer:
A Radiotherapy Comparative Effectiveness (RadComp)
Consortium Trial is a large-scale, multicentre pragmatic
randomised clinical trial following patients longitudinally
for cardiovascular morbidity and mortality, health-related
quality of life (HRQOL) and cancer control outcomes.
We focus on radiotherapy for breast cancer requiring
internal mammary nodal irradiation because: (1) regional
node radiotherapy is an important component of curative treatment for high risk breast cancer; (2) the survival
advantages of radiotherapy may be reduced by incidental
radiation to the heart; (3) proton therapy, by reducing
incidental radiation to the heart and other normal tissues,
may lead to meaningful reductions in cardiac morbidity
and mortality and improvements in HRQOL and (4)
patients with breast cancer seek evidence on disease
control, quality of life and cardiovascular outcomes after
proton versus photon therapy to help make shared decisions with their physicians about treatment options.
Our primary hypothesis is that proton therapy, as part
of multimodality curative treatment for patients with
non-metastatic breast cancer who have indications for
regional nodal irradiation, reduces major cardiovascular
events (MCEs) compared with photon therapy. MCEs are
defined as myocardial infarction, coronary revascularisation, cardiovascular death or hospitalisation for unstable
angina, heart failure, valvular disease, arrhythmia or
pericardial disease. Photon therapy, delivered as either
intensity-modulated radiotherapy or three-dimensional
(3D) conformal radiotherapy, uses multiple X-ray beams
to irradiate a tumour target but unavoidably deposits
radiation in normal tissues beyond the target volume. In
contrast, proton therapy directs a beam of protons (positively charged subatomic particles) at the target volume,
where they deposit the bulk of their energy in the last few
millimetres of their range.1 Proton radiation dose distributions may appear superior to photon therapy, particularly in the reduction of low and intermediate radiation
dose to normal tissues like the heart and lungs.
However, both photon and proton therapy have physical
and biological uncertainties that could impact important
clinical outcomes. For example, investigators have noted
uncertainties about the exact range of the proton therapy
in tissue and its biological effects at the end of the range.2
In addition, due to their distinct physical properties,
there may be differences in the biological effect of proton
therapy and photon therapy on normal tissues.
Thus, a broad range of stakeholders (patients,
providers, manufacturers, researchers and policy-makers)
have called for randomised evidence on the clinical
2

benefits and harms of proton therapy for patients with
breast cancer.3–9

Methods
Study design
This study is a superiority pragmatic randomised clinical
trial in breast cancer to compare two external beam radiation therapies: proton versus photon therapy. Treatment
techniques represent current care standards and are easy
to replicate. Study endpoints are assessed via self-report,
medical record review, vital records database search and
centralised adjudication. The primary outcome is assessed
by an adjudication team of cardiologists who are blinded
to treatment assignment.
Informed by the work of Sedrakyan, Luce, Ellenberg
and Treweek,10–14 the conceptual framework for the
trial (figure 1) addresses sources of variability that are
unique to radiation devices, including facility and device
characteristics.
The RadComp trial has in common a highly pragmatic
approach in most Pragmatic Explanatory Continuum Indicator Summary domains15 (table 1). We highlight three
choices essential to maintaining internal and external
validity: first, the trial is open label (both the researchers
and participants know which treatment is administered);
however, we conduct independent, centralised primary
outcome adjudication of MCEs to protect against differential misclassification between treatment groups.
Second, participant eligibility is minimally restricted,
without exclusions for pre-existing comorbidities, and
treatment is flexible in dosing and technique; however,
we provide the best practice guidelines for radiotherapy
delivery, consistent with prior pragmatic clinical trials of
technologically complex treatments (based on consensus
among RadComp centres).16 Third, treatment decisions
are at the discretion of the local treating providers and
patients; however, we will store radiotherapy treatment
plans within the RadComp Radiorepository for retrospective research review.
Overall aims
Aim 1 addresses the effectiveness of proton versus photon
therapy in reducing MCEs. Aim 2 assesses the non-inferiority of proton versus photon therapy in reducing risk of
breast cancer local-regional recurrence and in reducing
risk of any recurrence, defined as the first reported breast
cancer recurrence of any type (local-regional or distant
recurrence or cancer-specific mortality). Aim 3 considers
the effectiveness of proton versus photon therapy in
improving physical, mental and social HRQOL; specifically, body image and function in breast cancer, and
fatigue, anxiety, social roles, general HRQOL, side effects
burden and satisfaction. Aim 4 focuses on development
of predictive models to examine the associations of radiation dose distributions and MCE and HRQOL to identify
subgroups of patients most likely to benefit from proton
or photon therapy.
Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556
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Figure 1 Conceptual framework for randomised pragmatic clinical trial of proton versus photon therapy for locally advanced
breast: generating patient centric, real-word evidence.

Eligibility
Eligibility criteria are defined broadly to maximise generalisability of results, striking a balance between pragmatism and treatment appropriateness (table 2). Rarely,
patients will be ineligible if proton or photon therapy
cannot be administered safely.
Baseline assessments
Prior to randomisation, enrolled patients complete initial
assessments that include a patient interview and medical
record review to assess relevant prerandomisation covariates. Additional data regarding patient contact and alternate contacts information and baseline HRQOL are
collected.
Interventions
Patients are randomly assigned to receive either photon
or proton therapy. Participants are stratified by age (<65
vs ≥65), cardiovascular risk (0–2 vs >2 risk factors), surgery
(mastectomy vs lumpectomy) and laterality (left sided vs
right sided) (figure 2). Bilateral patients are classified as
left sided.
Proton therapy techniques may include passively scattered or scanning technology. All patients receive breast/
chest wall and comprehensive nodal radiation therapy
Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556

including internal mammary node treatment. Treatment
planning guidelines are described in the protocol, available on request. A contouring atlas has been developed
for guidance and is available at https://www.rtog.org/
CoreLab/ C ontouringAtlases/ R ADCOMPBreastAtlas.
aspx. A novel aspect of this atlas is that it can be viewed in
coronal, axial and sagittal planes by treating physicians.
RadComp Radiorepository
In a technology-based medical discipline like radiation oncology, significant centre-to-centre variations
exist in implementation of technologies.11 We draw a
balance between allowing for local practice variation
while promoting the best practice radiotherapy delivery
across centres; this effort is crucial to conduct a valid,
credible study, as well as to minimise the number of
patients required and maximise the protection of participants.17 18 The RadComp Radiorepository collects and
stores three-dimensional radiation treatment plans for
all patients through the data collection infrastructure
provided by The Cancer Imaging Archive (TCIA)19 20
to ensure efficiency of these processes for participating
centres. Data are stored in TCIA with the approval of the
National Cancer Institute (NCI), as a private collection
3
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Table 1 Key elements of the RadComp pragmatic
approach to study design
Domain

Typical explanatory
RCT

RadComp Pragmatic RCT

Blinding

Open label

Open label

Participant
eligibility

Highly selected (avoid
diluting effect)

Little selection beyond the
clinical indication for RT

Intervention
flexibility

Standardised, inflexible Flexible treatment
treatment guidelines
guidelines, promote local
care standards

Practitioner
expertise

Expert subspecialists at Academic and community
elite academic settings settings, real-world care

Follow-up

Frequent research
visits, more extensive
than routine care

Annual research visits, tied
to routine care; engage
patients

Primary
outcome

Clinically meaningful,
often surrogate

Clinically meaningful,
patient-centric MCE and
HRQOL

Event
adjudication

Variable

Independent, blinded,
centralised primary
outcome adjudication

Adherence

Stringent for both
patient and provider

Relaxed, usual care, best
practice recommendations

Analysis

Intention to treat

Intention to treat

Relevance to
practice

Indirect: trial design ≠
needs of stakeholders

Direct: trial design =
needs of patients and
stakeholders

HRQOL, health-related quality of life; MCE, major cardiovascular
event; RadComp, Radiotherapy Comparative Effectiveness; RCT,
randomised controlled trial; RT, radiation therapy.

and can be made publicly available at an appropriate time
following the completion of the trial.
Centralised adjudication of primary outcomes
The RadComp Clinical Events Centre (CEC) will conduct
centralised adjudication of clinical events related to the
primary outcomes of MCEs. The objectives of the CEC
are: (1) to apply consistent, simple, relevant definitions of
the fatal and non-fatal cardiovascular events comprising
the MCE endpoint to detect possible events and to avoid
the influence of investigator or patient ascertainment bias
and (2) to conduct adjudication blinded to treatment
assignment to protect against differential misclassification

Figure 2 Study stratification schema.

events. The goal of centralised adjudication of primary
outcomes is to increase confidence in the validity of
our findings.21–23 Leveraging the best practice adjudication procedures from the National Lung Screening
Trial24 and prior work at the University of Pennsylvania
in managing large, complex clinical event adjudication
programmes,25 26 the CEC employs key processes to
define, identify, track, investigate and determine whether
a primary event has occurred. The RadComp adjudication manual is available on request.
Outcomes, patient characteristics, and facility and device
characteristics
As shown in the conceptual framework, study measures
include primary outcomes (MCE), secondary outcomes,
baseline stratification factors, patient characteristics and
facility characteristics.
Major cardiovascular events
The primary outcome is MCE, defined as myocardial
infarction, coronary revascularisation, cardiovascular
death or hospitalisation for unstable angina, heart
failure, valvular disease, arrhythmia, or pericardial
disease.

Table 2 Summary of inclusion and exclusion criteria for the RadComp trial
Inclusion
criteria

Exclusion
criteria

►► Age ≥21 years.
►► Females or males diagnosed with pathologically (histologically) proven invasive mammary carcinoma

(ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy/local excision
with any type of axillary or internal mammary node chain surgery or sampling or who have had a local
recurrence.
►► Must be proceeding with breast/chest wall and nodal radiation therapy including internal mammary node
treatment.
►► Confirmation that participant’s health insurance or an alternative source will pay for the cost of proton or
photon therapy treatment on the study.
►► Definitive clinical or radiological evidence of metastatic disease.
►► Prior radiotherapy to the ipsilateral chest wall, breast or thorax.
►► Scleroderma.

RadComp, Radiotherapy Comparative Effectiveness.

4

Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556

BMJ Open: first published as 10.1136/bmjopen-2018-025556 on 15 October 2019. Downloaded from http://bmjopen.bmj.com/ on November 18, 2019 at Washington University School of
Medicine Library &. Protected by copyright.

Open access

Local-regional recurrence and any recurrence
The primary cancer control outcome is local-regional
recurrence, defined as the local recurrence as a first
event.27–29 We will also evaluate any recurrence, defined
as the first reported breast cancer recurrence of any type
(local-regional or distant recurrence or cancer-specific
mortality).
Baseline cardiovascular disease
Assessed at baseline, elevated risk of cardiovascular
disease is defined by a history of coronary artery disease
or myocardial infarction, atrial fibrillation/flutter, hypertension, diabetes, renal failure, hyperlipidaemia, heart
failure, cardiomyopathy, smoking (current/former),
prior contralateral left breast or chest wall radiation, prior
anthracycline therapy or prior trastuzumab therapy. We
choose this approach as both valid (based on the Framingham risk score) and consistent with our pragmatic
framework, acknowledging that some cardiovascular risk
stratification schemes include laboratory or echocardiographic assessment.30 Other cardiovascular risk factors
(including family history) will be assessed but will not
contribute to the definition of cardiovascular risk factors
for the purposes of stratification.
Patient characteristics
We will collect demographic information including
gender, race, ethnicity, marital status, educational attainment, insurance, household income, comorbidity assessment and disease severity, leveraging the Patient-Reported
Outcomes Measurement Information System (PROMIS)
sociodemographic and comorbidity questionnaire.31
Facility/device characteristics and radiation dose distribution
We will investigate the relationship between proton and
photon dose distribution metrics and differences in MCE
and HRQOL in order to identify subgroups of patients
that might benefit from proton or photon therapy. To
facilitate this analysis, we will record patient-level radiation dose distributions and treatment delivery parameters,
facility and device radiation technical characteristics, and
any evolution of radiation techniques over time through
the RadComp Radiorepository. We also will conduct
centralised contouring of organs at risk, including the
heart and its substructures (left anterior descending
artery, left and right atria, left and right ventricles, left
main, left circumflex and the right coronary artery,
lungs, oesophagus and thyroid). Centralised contouring
is important in any radiotherapy trial but is particularly
pertinent to a pragmatic trial in which the local norms
of anatomic delineation for radiation treatment planning
vary widely.32 33 While patients will be treated according
to anatomic delineation of local providers, centralised
contouring will be conducted by trained staff at the
RadComp Coordinating Centre and the results stored
in the Radiorepository. Participating sites must submit
a facility questionnaire, complete a physics plan review
Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556

and demonstrate successful digital data submission to the
Radiorepository prior to study initiation.
HRQOL instruments
The HRQOL instruments and outcomes chosen for the
proposed trials are hypothesis driven, validated, reliable
and have been shown to be meaningful to patients.34–37
Each instrument is described below. The estimated
patient response burden to complete these instruments is
approximately 30 min.
Functional Assessment of Cancer Therapy-Breast
The Functional Assessment of Cancer Therapy-Breast
(FACT-B) measures general and breast cancer-specific
HRQOL.38 It has multiple subscales, three of which are
combined to form a Trial Outcome Index that is useful
for clinical trials. It also has a four-item arm mobility
subscale39 40 and two items to measure pain and swelling.
BREAST-Q
The BREAST-Q was designed to evaluate outcomes among
women undergoing different types of breast surgery.41 A
five-item subscale to assess adverse effects of radiotherapy
will be used in this trial.
Satisfaction with breast cosmetic outcomes
This six-item scale was developed to provide a brief assessment of patient-reported cosmetic outcomes after breast
cancer treatment.42
PROMIS fatigue
The four-item fatigue short form combines items on
fatigue experience and interference derived from the
Functional Assessment of Chronic Illness Therapy
(FACIT) system and PROMIS.31 43–45 It has been used
extensively in oncology trials and is responsive to change
after radiation therapy.
PROMIS anxiety
Anxiety is a common concern among patients with
cancer34 and is especially relevant for the RadComp trials.
The PROMIS 4-item short form for Anxiety was developed based on content and psychometric measurement
precision.46
PROMIS social roles
Social function has historically been a relatively neglected
domain due to the lack of measures for clinical populations. A four-item PROMIS short form will be used in
this trial, derived from the validated a 35-item measure of
ability to participate in social roles and activities.47
This side effects short form will solicit experience,
shortness of breath and chest pain. Items were selected
from the NCI’s Patient-Reported Outcomes version of
the Common Terminology Criteria for Adverse Events
(PRO-CTCAE) system, which was developed to collect
patient reports of symptoms they are experiencing while
undergoing treatment, for the purpose of enhancing
adverse event (AE) reporting (http://healthcaredelivery.
5
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cancer.gov/pro-ctcae/) or were written for this trial using
the PRO-CTCAE format. A single item from the FACT-B
will also be used to measure the overall burden of side
effects (‘I am bothered by side effects of treatment: not at
all, a little bit, somewhat, quite a bit, very much’), as used
in prior cancer studies.48–50
Functional Assessment of Chronic Illness Therapy-Treatment
Satisfaction-General
The FACIT system includes an eight-item measure of
general satisfaction with treatment, developed and validated with patients with cancer and HIV/AIDS.51 Six of
the eight items will be used in this trial.
Financial burden
In discussion with the stakeholder advisory committee, we
included an item to assess overall financial burden. This
item is part of the European Organization for Research
and Treatment of Cancer QLQ-C30 instrument: ‘Has
your physical condition or medical treatment caused you
financial difficulties?’ (not at all, a little bit, quite a bit,
very much).52
Productivity
This single item has been developed to assess the extent
that a patient was able to resume normal activities. It is
rated on a 0%–100% scale.53
EuroQOL-5D
The EuroQOL-5D is a standardised two-part, self-administered instrument for direct and indirect assessment of
health state utilities; it is cognitively simple, takes only a
few minutes to complete and yields a utilities index value
for health status.54
Recruitment
All patients will be recruited in clinic settings between
the time of presentation with breast cancer and prior to
start of radiation therapy. Radiation oncologists at each
recruiting site will assess willingness for their patients to
be enrolled.
RadComp recruiting sites have been selected to represent a broad range of geographic locations and practice settings in the USA, including large teaching and
non-teaching treatment centres and smaller community
facilities. The site selection process for RadComp included
consideration of volume of patients with breast cancer,
treatment practices and presence of buy-in from clinical
leaders. Over 95% of existing proton therapy treatment
centres in the USA are participating in the trial.
AE monitoring
At each contact with the subject, including the pretreatment assessment, the investigator seeks information
on AEs by specific questioning and, as appropriate, by
examination. AEs will be recorded by clinicians using
the National Cancer Institute Common Toxicity Criteria
for Adverse Events (CTCAE) V.4.0, a comprehensive,
6

multimodality grading system for reporting the acute and
late effects of cancer treatment.55
Data analysis and management
Analyses for all endpoints will follow the intention-to-treat
principle. As-treated analyses will be conducted for MCEs
and other safety endpoints secondarily. The primary analysis will be a comparison of time to MCE between treatment
arms. Log-rank tests will be used to compare the time to
MCE between treatment arms; Kaplan-Meier plots will be
used to graphically depict time to MCE by treatment arm.
The main subgroups assessed for heterogeneity of treatment effects (HTE) within Cox models will be the stratification factors as defined in the schema. In secondary
analyses, we will assess the influence of patient characteristics (gender, race, ethnicity, marital status, education,
health literacy, income, insurance status, comorbidities
and disease severity) and device and facility characteristics (radiation dose distribution, facility and device radiation technical characteristics, change in technique over
time). To account for the presence of competing risks,
we also will conduct secondary analyses of the cumulative incidence of MCE using non-parametric cumulative
incidence functions. We will use the Fine-Gray semiparametric model for subdistribution hazards to estimate the
effects of stratification factors and other covariates.
Initial evaluation of HTE will be made by analysis of
interactions between treatment and patient-level and
facility/device covariates using a Cox regression model
with the primary outcome (MCE) as the dependent variable. Treatment effects within subgroups, such as ethnicity
and race, will be conducted if any treatment–covariate
interactions are at least suggestive (p<0.20) and sample
sizes and numbers of events within these subgroups are
sufficient for analysis. Due to the exploratory nature of
these analyses and the expected limited sample size in
each subgroup, no adjustments for multiple comparisons will be made. These analyses will follow the primary
comparisons as specified for MCE.
Power and sample size
Our primary hypothesis is that treatment with proton
therapy as compared with photon therapy will reduce the
rate of MCEs.
The study will randomise 1278 patients to photon
therapy versus proton therapy for treatment of breast
cancer. The 10-year estimate of the proportion of patients
with breast cancer with MCEs in the photon arm is estimated to be 6.3% based on study team analyses of data
from the Surveillance Epidemiological End Results database (available on request from the authors). Assuming
a 45% relative reduction of MCEs using proton therapy,
resulting in an MCE rate of 3.5% for the proton arm,
this sample will provide 80% power to detect this difference between the two arms using a log-rank test with a
one-sided alpha of 0.05. A sample size of 1278 will allow
sufficient power with a loss to follow-up rate of 13%.
Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556
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The planned sample size will also provide sufficient
power for testing hypotheses related to our secondary
outcomes. An underlying assumption is that proton
therapy will not negatively impact cancer control
outcomes. This assumption is biologically plausible given
similar radiation doses and biological effects of protons
and photons on tumour bed targets; yet, clinical evidence
is scarce. We plan to evaluate local-regional relapse, the
primary cancer control outcome of interest for radiation,
using a non-inferiority approach. Non-inferiority margins
were evaluated based on prior studies showing improvements in local-regional relapse rates with photon therapy,
relative to no radiation.28 29 With a sample size of 1278
patients, there is 80% power for a 5-year non-inferiority
margin not higher than 3.8% for local-regional recurrence assuming local-regional recurrence in the photon
arm of 5% at 5 years using a log-rank test with a one-sided
alpha of 0.025. We will examine cancer-specific and
overall survival according to methods described above for
time-to-event analyses.
For HRQOL outcomes, effect sizes were estimated as
the expected difference between groups at the 6-month
assessment. A correlation of 0.40–0.60 between repeated
measures was assumed, based on data from previous longitudinal studies of HRQOL and satisfaction in patients with
cancer.56–58 An effect size of 0.33 corresponds to a clinically important difference in HRQOL outcomes.59 60 The
proposed sample sizes in each treatment arm (n=650) will
be sufficient to detect an effect size of 0.33 under various
scenarios. For example, even with a correlation as low as
0.40, 174 patients per treatment arm will provide power
of 80% at a two-sided significance level of 0.05. Adjusting
for multiple primary endpoints in the breast cancer trial,
330 patients per treatment arm will provide power of
90% at a two-sided significance level of 0.01. There will
be adequate statistical power even with assuming 15%
drop-out.
Study monitoring
The Radiation Therapy Oncology Group Foundation
data monitoring committee (DMC) will review the study
twice a year with respect to patient accrual and morbidity,
and at any other times on an ‘as needed’ basis. The
review of the study will include, but not be limited to, the
following items: accrual, baseline demographic characteristics, withdrawal rates, toxicity data, protocol compliance, treatment arm-specific data including radiation
dose, toxicity and compliance, HRQOL questionnaire
compliance, interim analyses of AEs and safety results
and outcome analyses results. Data by treatment arm will
be seen only by the DMC, which will assess the integrity
of the accruing data and compare selected measures
between treatment arms that may affect study validity or
raise potential ethical concerns regarding safety.
Patient and public involvement
Since 2009, leaders of the RadComp Consortium have
convened or participated in workgroups of patients,
Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556

clinicians, methodologists, cancer researchers, payers,
product developers, vendors and government representatives to explore the feasibility of alternative efficacy and
effectiveness study designs and to build momentum for
comparative studies of proton and photon therapy (These
efforts resulted in the currently accruing NCI-sponsored
efficacy PARTIQoL trial).61–63 In 2014, RadComp investigators called for randomised trial evidence generation
for proton therapy in breast and lung cancer64 and the
current multi-institutional RadComp Consortium of 22
proton/photon centres agreed to seek Patient-Centered
Outcomes Research Institute funding for a pragmatic
randomised clinical trial. In June 2014, in partnership
with the NCI’s Radiation Research Branch, the Consortium hosted a stakeholder engagement meeting on the
NCI campus, in which we gained important insights on
the formulation of the research questions, study designs,
study implementation plans and other key characteristics
of comparative effectiveness research.3
We learnt from stakeholders that one essential challenge in conducting randomised trials of proton therapy
is restrictive insurance coverage for proton therapy, particularly for breast cancer.65 While Medicare typically covers
proton therapy for breast cancer indications, commercial
insurers are more restrictive; however, reasonable clinical
rationale supports coverage of radiation modalities such as
intensity-modulated photon therapy or proton therapy for
patients with breast cancer who require internal mammary
node treatment (that is, patients with breast cancer clinically eligible for RadComp). Restrictive commercial
coverage policies for proton therapy may impact the pace
of enrolment to RadComp and the generalizability of the
results. Therefore, RadComp engages with stakeholders to
develop potential solutions to support for trial participation
for eligible and interested patients.
The Stakeholder Advisory Committee and the larger
stakeholder group have and will continue to participate
in stakeholder deliberations. The Stakeholder Advisory
Committee provides their insight on: (1) the creation of
strategies to recruit and retain all patient populations,
(2) developing study talking points in plain language
to overcome patient confusion or fear of the concept
of equipoise/uncertainty among treatment options, (3)
translating study findings and (4) mechanisms for the
broad dissemination and implementation of the best
practices.
Ethics and dissemination
Of currently approved sites, nine have designated the
University of Pennsylvania IRB as the IRB of record.
Recruitment began in February 2016 and will continue
through the end of 2021. Changes to the protocol will
be communicated via teleconferences and memos to all
sites with an expected date of implementation. Training
on the changes will be documented.
Protected health information is only shared with
research team members as required for completion of
designated study tasks. Patient contact information for
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follow-up is only transmitted to the coordinating centre
via secure network servers. All team members needing
access to identifiable study data will be required to submit
appropriate trainings and roster forms to request access.
Logs of dates and times of database accessed will be kept,
including an audit trail of data changes.

Conclusion
The RadComp trial will evaluate outcomes after proton or
photon therapy for patients with breast cancer through a
real-world, patient-centred pragmatic randomised clinical
trial. RadComp’s goal is to generate new knowledge about
the relative effects of these approaches while ensuring that
treatment reflects high-quality routine clinical practice,
identifies subgroups of patients that might benefit more
from either treatment, and helps patients and physicians
understand and apply our findings to their own experience. Patients with breast cancer considering photon or
proton therapy make treatment decisions in the context of
extremely sparse comparative effectiveness evidence, and
then may live for years with clinically burdensome treatment-related morbidity that affects their quality of life and
engagement in activities of living. The RadComp trial results
will be directly relevant to many thousands of patients who
confront these difficult treatment decisions every day.
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